Cue Biopharma CEO Daniel Passeri's 2023 pay jumps 119% to $3M
Cue Biopharma reports 2023 executive compensation
By ExecPay News
Published: April 26, 2024
Cue Biopharma reported fiscal year 2023 executive compensation information on April 26, 2024.
In 2023, three executives at Cue Biopharma received on average a compensation package of $1.8M, a 51% increase compared to previous year.
Average pay of disclosed executives at Cue Biopharma
Daniel R. Passeri, Chief Executive Officer, received $3M in total, which increased by 119% compared to 2022. 80% of Passeri's compensation, or $2.4M, was in option awards. Passeri also received $605K in salary and $3.2K in other compensation.
Anish Suri, Chief Scientific Officer, received a compensation package of $1.2M, which increased by 6% compared to previous year. 61% of the compensation package, or $758K, was in option awards.
Kerri-Ann Millar, Chief Financial Officer, earned $1.2M in 2023, a 10% increase compared to previous year.
Related executives
You may also like
Source: SEC filing on April 26, 2024.